STTK
STTK clinical trials: Shattuck Labs, Inc.
Every trial on ClinicalTrials.gov where Shattuck Labs, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
STTK on the catalyst calendar · STTK registry changes
- Primary completion Jul 16, 2026ActualPhase 1NCT07158437Phase 1 Study of SL-325 in Healthy VolunteersShattuck Labs, Inc. · Healthy VolunteersCompletedSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 2NCT07934017A Study of SL-325 in Participants With Hidradenitis SuppurativaShattuck Labs, Inc. · Hidradenitis Suppurativa (HS)Not yet recruitingSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 2NCT07753850A Study of SL-325 in Crohn's Disease PatientsShattuck Labs, Inc. · Crohn's DiseaseRecruitingSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 6, 2025ActualPhase 1NCT05275439Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLShattuck Labs, Inc. · Acute Myeloid LeukemiaTerminatedSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 7, 2025ActualPhase 1NCT05483933Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersShattuck Labs, Inc. · Platinum-resistant Ovarian CancerCompletedSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 4, 2023ActualPhase 1NCT03894618SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasShattuck Labs, Inc. · Squamous Cell Carcinoma of the Head and NeckCompletedSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2022ActualPhase 1NCT04502888Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or SkinShattuck Labs, Inc. · Cutaneous Squamous Cell CarcinomaTerminatedSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2023ActualPhase 1NCT04406623Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerShattuck Labs, Inc. · Ovarian CancerCompletedSTTKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner